Key Points
- United Therapeutics EVP Paul Mahon sold 11,000 shares on Dec. 24 at an average price of $513.18 for about $5.645 million, reducing his direct stake by 23.02% to 36,781 shares, according to an SEC filing.
- Company results and sentiment: UTHR reported quarterly EPS of $7.16 (beating estimates) with revenue of $799.5M (slightly below forecasts) and strong margins, and analysts maintain a "Moderate Buy" consensus with an average target of $505 and several price-target upgrades in the $525–$600 range.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 11,000 shares of the business's stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $513.18, for a total value of $5,644,980.00. Following the sale, the executive vice president directly owned 36,781 shares in the company, valued at $18,875,273.58. This trade represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
United Therapeutics Stock Down 0.8%
NASDAQ:UTHR opened at $502.90 on Tuesday. The stock has a fifty day simple moving average of $472.78 and a 200 day simple moving average of $390.12. The firm has a market capitalization of $21.65 billion, a price-to-earnings ratio of 19.06, a price-to-earnings-growth ratio of 5.04 and a beta of 0.86. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating analysts' consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. During the same period in the prior year, the firm earned $6.39 earnings per share. The business's quarterly revenue was up 6.8% on a year-over-year basis. Equities analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Institutional Investors Weigh In On United Therapeutics
A number of large investors have recently bought and sold shares of the business. Clearstead Advisors LLC increased its position in United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company's stock worth $117,000 after buying an additional 23 shares during the last quarter. Bessemer Group Inc. lifted its position in shares of United Therapeutics by 2.6% in the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company's stock worth $472,000 after buying an additional 28 shares during the last quarter. Archer Investment Corp boosted its stake in shares of United Therapeutics by 9.5% during the 3rd quarter. Archer Investment Corp now owns 356 shares of the biotechnology company's stock worth $149,000 after acquiring an additional 31 shares in the last quarter. F m Investments LLC increased its holdings in shares of United Therapeutics by 1.3% during the 2nd quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company's stock valued at $741,000 after acquiring an additional 33 shares during the last quarter. Finally, HB Wealth Management LLC increased its holdings in shares of United Therapeutics by 2.9% during the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company's stock valued at $355,000 after acquiring an additional 35 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of research analysts recently commented on the stock. Royal Bank Of Canada boosted their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an "outperform" rating in a research report on Thursday, October 30th. UBS Group boosted their price target on shares of United Therapeutics from $580.00 to $600.00 and gave the company a "buy" rating in a report on Thursday, November 6th. Cantor Fitzgerald increased their price objective on United Therapeutics from $405.00 to $525.00 and gave the stock an "overweight" rating in a report on Wednesday, September 10th. Jefferies Financial Group restated a "buy" rating and issued a $575.00 target price on shares of United Therapeutics in a research note on Wednesday, November 19th. Finally, HC Wainwright upped their target price on United Therapeutics from $500.00 to $525.00 and gave the stock a "buy" rating in a research report on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $505.00.
View Our Latest Report on UTHR
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
